Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of AGMB-447 in idiopathic pulmonary fibrosis
NL-OMON61800Phase 2Not yet recruiting
- Sponsor
- Agomab Therapeutics
- Start
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of AGMB-447 in idiopathic pulmonary fibrosis (IPF), sponsored by Agomab Therapeutics. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
AGMB-447
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NL-OMON61800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61800.